These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24028772)

  • 21. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
    Oldenburg J; Jiménez-Yuste V; Peiró-Jordán R; Aledort LM; Santagostino E
    Haemophilia; 2014 Jan; 20(1):83-91. PubMed ID: 24354480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factor.
    Mazurier C; de Romeuf C; Parquet-Gernez A; Jorieux S; Goudemand M
    Vox Sang; 1987; 52(4):265-71. PubMed ID: 3114955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
    Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
    Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels.
    Fijnvandraat K; Peters M; ten Cate JW
    Br J Haematol; 1995 Oct; 91(2):474-6. PubMed ID: 8547097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelets compensate for poor thrombin generation in type 3 von Willebrand disease.
    Szanto T; Nummi V; Jouppila A; Brinkman HJM; Lassila R
    Platelets; 2020; 31(1):103-111. PubMed ID: 30836803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.
    Schütte LM; Cnossen MH; van Hest RM; Driessens MHE; Fijnvandraat K; Polinder S; Beckers EAM; Coppens M; Eikenboom J; Laros-van Gorkom BAP; Meijer K; Nieuwenhuizen L; Mauser-Bunschoten EP; Leebeek FWG; Mathôt RAA; Kruip MJHA
    BMJ Open; 2019 Apr; 9(4):e022719. PubMed ID: 31015264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
    Viswabandya A; Mathews V; George B; Nair SC; Baidya S; Mammen JJ; Chandy M; Srivastava A
    Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelets significantly modify procoagulant activities in haemophilia A.
    Wartiovaara-Kautto U; Joutsi-Korhonen L; Ilveskero S; Armstrong E; Lassila R
    Haemophilia; 2011 Sep; 17(5):743-51. PubMed ID: 21682825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Normal cleavage of von Willebrand factor by ADAMTS-13 in the absence of factor VIII in patients with severe hemophilia A.
    Chen J; Chung DW; Le J; Ling M; Konkle BA; López JA
    J Thromb Haemost; 2013 Sep; 11(9):1769-72. PubMed ID: 23682841
    [No Abstract]   [Full Text] [Related]  

  • 32. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.
    Samuelson Bannow B; Recht M; Négrier C; Hermans C; Berntorp E; Eichler H; Mancuso ME; Klamroth R; O'Hara J; Santagostino E; Matsushita T; Kessler C
    Blood Rev; 2019 May; 35():43-50. PubMed ID: 30922616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
    Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A
    Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
    Dmoszynska A; Hellmann A; Baglin T; O'Shaugnessy D; Trelinski J; Kuliczkowski K; Kloczko J; Hay C; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
    Haemophilia; 2011 Mar; 17(2):185-90. PubMed ID: 21070496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor VIII recovery after a single infusion of recalibrated ReFacto in 14 severe haemophilia A patients.
    Lambert T; Guérois C; Gay V; Stieltjes N; Bertrand MA; Derlon A; Sigaud M; Hassoun A; Négrier C; Coatmelec B; Dreyfus M; Dubanchet A
    Haemophilia; 2007 Jul; 13(4):357-60. PubMed ID: 17610548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
    Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
    Jacquemin M
    Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of VWF in the immunogenicity of FVIII.
    Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
    Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
    Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
    Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.